Beta Bionics priced an underwritten public offering expected to generate $150.0 million in gross proceeds, comprising 7,652,175 common shares at $17.25 each and pre-funded warrants for 1,043,484 shares at $17.2499 each. Shares fell 7.1% to $17.87 in pre-market trading. The company expects to use net proceeds for Mint commercialization, manufacturing expansion, research and clinical development, product enhancements, strategic opportunities, working capital and operating expenses; closing is expected around September 17, 2026, subject to customary conditions.